Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation

Miller, A. and McInnes, I. (2011) Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation. Current Pharmaceutical Design, 17(1), pp. 1-8. (doi: 10.2174/138161211795049796) (PMID:21222645)

Full text not currently available from Enlighten.


Patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, psoriasis and Crohn's disease have an increased atherosclerotic risk which cannot be explained by traditional cardiovascular risk factors alone. Inflammatory pathways are implicated in this increased vascular risk. The involvement of cytokine – related signaling pathways in inflammatory diseases has prompted the development of many therapeutic strategies aimed at their modulation to limit disease severity and progression. Whether modulation of these pathways would similarly alter the inflammatory processes related to accelerated atherosclerosis remains unknown. In this review we will focus on the role of pro-inflammatory cytokines and their inhibitors in RA, and whether they may be causal in the accelerated atherosclerosis seen in these patients.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Miller, Dr Ashley
Authors: Miller, A., and McInnes, I.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Current Pharmaceutical Design
Publisher:Bentham Science Publishers

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
483611Interleukin-33: A Novel Cytokine in the Inflammation of Atherosclerosis and ObesityAshley MillerBritish Heart Foundation (BHF)FS/08/035/25309Infection Immunity and Inflammation Medicine